Title |
RPN2-mediated glycosylation of tetraspanin CD63 regulates breast cancer cell malignancy
|
---|---|
Published in |
Molecular Cancer, May 2014
|
DOI | 10.1186/1476-4598-13-134 |
Pubmed ID | |
Authors |
Naoomi Tominaga, Keitaro Hagiwara, Nobuyoshi Kosaka, Kimi Honma, Hitoshi Nakagama, Takahiro Ochiya |
Abstract |
The tetraspanin CD63 is a highly N-glycosylated protein that is known to regulate cancer malignancy. However, the contribution of glycosylation of CD63 to cancer malignancy remains unclear. Previously, we reported that ribophorin II (RPN2), which is part of an N-oligosaccharyle transferase complex, is responsible for drug resistance in breast cancer cells. In this study, we demonstrate that cancer malignancy associated with the glycosylation of CD63 is regulated by RPN2. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 50% |
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 93 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 93 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 23 | 25% |
Student > Bachelor | 15 | 16% |
Researcher | 13 | 14% |
Student > Master | 11 | 12% |
Professor > Associate Professor | 5 | 5% |
Other | 8 | 9% |
Unknown | 18 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 23 | 25% |
Agricultural and Biological Sciences | 20 | 22% |
Medicine and Dentistry | 11 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
Neuroscience | 3 | 3% |
Other | 7 | 8% |
Unknown | 26 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 January 2017.
All research outputs
#6,405,709
of 22,756,196 outputs
Outputs from Molecular Cancer
#447
of 1,718 outputs
Outputs of similar age
#61,075
of 226,965 outputs
Outputs of similar age from Molecular Cancer
#9
of 48 outputs
Altmetric has tracked 22,756,196 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 1,718 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,965 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.